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Abstract 
Background: Microvascular disease is associated with a high risk of macrovascular events in patients with type 2 
diabetes, but the impact of macrovascular disease on the risk of microvascular events remains unknown. We sought 
to evaluate the respective effects of prior microvascular and macrovascular disease on the risk of major outcomes, 
including microvascular events, in these patients.
Methods: Participants in the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Con-
trolled Evaluation (ADVANCE) trial (n = 11,140) and the ADVANCE-ON post-trial study (n = 8494) were categorized 
into 4 groups at baseline: dual absence of microvascular or macrovascular disease (n = 6789), presence of microvas-
cular disease alone (n = 761), macrovascular disease alone (n = 3196), and both (n = 394). Outcomes were all-cause 
mortality, major macrovascular events (MACE), and major clinical microvascular events.
Results: All-cause mortality, MACE, and major clinical microvascular events occurred in 2265 (20%), 2166 (19%), 
and 807 (7%) participants respectively, during a median follow-up of 9.9 (inter-quartile interval 5.6–10.9) years. The 
adjusted hazard ratios [95% CI] of death, MACE, and major clinical microvascular events were each greater in patients 
with baseline microvascular disease (1.43 [1.20–1.71], 1.64 [1.37–1.97], and 4.74 [3.86–5.82], respectively), macrovascu-
lar disease (1.43 [1.30–1.57], 2.04 [1.86–2.25], and 1.26 [1.06–1.51]) or both (2.01 [1.65–2.45], 2.92 [2.40–3.55], and 6.30 
[4.93–8.06]) compared with those without these conditions. No interaction was observed between baseline micro-
vascular and macrovascular disease for these events. The addition of microvascular disease (change in c-statistic [95% 
CI] 0.005 [0.002–0.008], p = 0.02) or macrovascular disease (0.005 [0.002–0.007], p < 0.0001) considered separately or 
together (0.011 [0.007–0.014], p < 0.0001) improved the discrimination and the classification (integrated discrimina-
tion improvement (IDI): 0.013 [0.010–0.016], p < 0.001; net reclassification improvement (NRI): 0.021 [0.011–0.032], 
p < 0.001) of the risk of all-cause mortality. Microvascular disease improved discrimination (0.009 [0.003–0.014]) and 
classification (IDI: 0.008 [0.006–0.010]; NRI: 0.011 [0.001–0.020]) of MACE. Baseline macrovascular disease modestly 
enhanced IDI (0.002 [0.001–0.002]) and NRI (0.041 [0.002–0.087]), but not discrimination, of major clinical microvascu-
lar events.
Conclusions: Microvascular and macrovascular disease are independently associated with the 10-year risk of death, 
MACE, and major clinical microvascular events in patients with type 2 diabetes. The coexistence of these conditions 
was associated with the highest risks.
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Background
Type 2 diabetes is a leading cause of microvascular 
complications and confers an excess risk of cardiovas-
cular disease and death [1, 2]. Microvascular and mac-
rovascular complications often occur concomitantly, 
and share similar risk factors and pathological pathways 
[3–5]. The presence of microvascular disease increases 
the risk of cardiovascular morbidity and mortality in 
people with type 2 diabetes, independent of the major 
established cardiovascular risk factors [6]. However, the 
impact of macrovascular disease on the risk of microvas-
cular events has not been fully investigated. We sought 
to evaluate the impact of microvascular and macrovas-
cular disease, considered individually, and together, on 
the risk of death and major macrovascular and micro-
vascular events in patients with type 2 diabetes partici-
pating in the Action in Diabetes and Vascular Disease: 
PreterAx and DiamicroN Modified-Release Controlled 
Evaluation (ADVANCE) trial (ClinicalTrials.gov Num-
ber, NCT00145925) and ADVANCE-ON post-trial study 
(ClinicalTrials.gov Number, NCT00949286).
Materials and methods
Participants
ADVANCE was a multi-national randomized trial testing 
the effect of intensive glucose control (using a gliclazide-
MR) and routine blood pressure treatment (using a fixed-
dose combination of perindopril and indapamide) on the 
risk of major microvascular and macrovascular events 
in 11,140 patients with type 2 diabetes and at least one 
other cardiovascular risk factor or pre-existing cardiovas-
cular disease [7–9]. Subsequently, 8494 of the surviving 
participants were enrolled in the post-trial observational 
study (ADVANCE-ON). The design and characteristics 
of participants have been previously described [8–10]. 
The Institutional Ethics Committee of each participat-
ing centre approved the ADVANCE and ADVANCE-ON 
protocols, and all participants provided written informed 
consent.
Definition of microvascular and macrovascular disease 
at baseline
At baseline, microvascular disease was defined as the 
presence of macroalbuminuria (urinary albumin to cre-
atinine ratio (ACR) >300  mg/g), requirement of reti-
nal photocoagulation therapy, proliferative retinopathy, 
macular oedema, or diabetes-related blindness. Mac-
rovascular disease was defined as the presence, at base-
line, of myocardial infarction, stroke, coronary artery 
bypass graft, percutaneous transluminal coronary angio-
plasty, hospital admission for unstable angina or tran-
sient ischaemic attack, lower-extremity amputation of 
at least one digit secondary to arterial insufficiency, or a 
peripheral revascularisation procedure. Participants were 
categorized into four baseline groups: absence of both 
microvascular and macrovascular disease, presence of 
microvascular disease alone, presence of macrovascular 
disease alone, and presence of both microvascular and 
macrovascular disease.
Definition of outcomes
The primary outcomes were all-cause mortality, major 
macrovascular events (MACE: a composite of nonfatal 
myocardial infarction, nonfatal stroke, or cardiovascu-
lar death), and major clinical microvascular events (a 
composite of end-stage renal disease (ESRD), defined 
as requirement for renal-replacement therapy; death 
induced by renal disease; requirement for retinal photo-
coagulation; or diabetes-related blindness in either eye). 
The secondary outcomes were cardiovascular death, fatal 
or nonfatal myocardial infarction, fatal or nonfatal stroke, 
ESRD or renal death, and requirement for retinal photo-
coagulation or blindness. Outcomes were adjudicated by 
an independent End Point Adjudication Committee in 
the ADVANCE trial, through to the end of randomized 
allocation, and were reported by investigators without 
adjudication in the ADVANCE-ON study, in accordance 
with its pre-specified protocol [10].
Statistical analyses
Continuous variables were summarized as mean (SD) 
or, for those with a skewed distribution, median (inter-
quartile range). Categorical variables were summarized 
as the number of patients with corresponding percent-
age. Characteristics of participants according to status 
of microvascular and macrovascular disease at baseline 
were compared using Chi squared, ANOVA, or Kruskal–
Wallis tests.
Cumulative incidence curves were used to plot sur-
vival (outcome-free) rates during follow-up, and com-
pared using the log-rank test. Cox proportional hazards 
regression models were fitted to estimate hazard ratios 
(HRs), with associated 95% confidence intervals (CI), for 
outcomes by joint status of microvascular and macro-
vascular disease at baseline. Analyses were adjusted for 
randomized study allocations plus every potential con-
founding variable that was significantly different between 
microvascular and macrovascular disease at baseline: sex, 
age, region of origin (Asia: Philippines, China, Malaysia, 
and India; established market economies: Australia, Can-
ada, France, Germany, Ireland, Italy, Netherlands, New 
Zealand, United Kingdom; and Eastern Europe: Czech 
Republic, Estonia, Hungary, Lithuania, Poland, Russia, 
Slovakia), body mass index, duration of diabetes, HbA1c, 
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systolic blood pressure, antihypertensive treatment, 
estimated glomerular filtration rate (eGFR; computed 
by the Chronic Kidney Disease–Epidemiology Col-
laboration equation [11]) and its square, urinary ACR, 
LDL- and HDL-cholesterol, and history of ever smoking 
(basic model). The proportional hazards assumption was 
checked using the Schoenfeld residuals method.
We tested multiplicative interaction between baseline 
history of microvascular disease and macrovascular dis-
ease on the risk of each outcome by including these two 
individual variables and their product within Cox models.
Harrell’s c-statistic [12], net reclassification improve-
ment (NRI) and integrated discrimination improvement 
(IDI) were used to compare discrimination and clas-
sification of primary outcomes, assessed using survival 
methodology, between two prognostic models: basic 
model and basic model plus baseline history of micro-
vascular or macrovascular disease (as appropriate). Since 
we assessed the additive value of microvascular disease 
(including macroalbuminuria) on the risk of all-cause 
mortality and MACE, urinary ACR was not included in 
the basic model in these analyses. We also evaluated the 
individual and joint prognostic value of urinary ACR (as 
a continuous variable) and diabetic retinopathy, added to 
the basic model, on the discrimination of all-cause mor-
tality and MACE.
Sensitivity analyses were conducted after including fur-
ther components of microvascular disease at baseline: (i) 
chronic kidney disease (CKD defined as eGFR <60  ml/
min/1.73  m2) or (ii) diabetic peripheral neuropathy 
(defined as a disturbance of 10-g monofilament sensation 
or absence of ankle reflex in both feet). We also evaluated 
the associations of microvascular and macrovascular dis-
ease at baseline on the risk of MACE and major clinical 
microvascular events after treating non-renal and non-
cardiovascular death as a competing risk using the Fine 
and Gray method [13].
Statistical analyses were performed using SAS software, 
version 9.3 (SAS Institute, www.sas.com), and Stata soft-
ware version 13 (StataCorp, www.stata.com). A P value 
less than 0.05 was considered significant.
Results
Clinical characteristics at baseline
Among 11,140 participants enrolled in ADVANCE trial, 
761 (6.8%) had microvascular disease alone, 3196 (28.7%) 
had macrovascular disease alone, and 394 (3. 5%) had 
both at baseline (Additional file  1: Table S1). Patients 
with microvascular disease alone at baseline had a longer 
duration of diabetes and higher HbA1c, systolic blood 
pressure, and ACR levels, whereas those with macro-
vascular disease alone were more frequently men, from 
established market economies, ever smokers, and treated 
with antihypertensive, lipid lowering and antiplatelet 
drugs (Table 1).
Incidence of major outcomes during follow‑up according 
to status of microvascular and macrovascular disease 
at baseline
All-cause mortality, MACE, and major clinical micro-
vascular events occurred in 2265 (20.3%), 2166 (19.4%), 
and 807 (7.2%) participants, respectively, during a 
median overall follow-up of 9.9 (inter-quartile interval 
5.6–10.9)  years. Their incidence rates were 2.4, 2.4, and 
0.9 per 100 person-years, respectively. The risks of these 
respective outcomes were higher in patients with baseline 
history of only microvascular (HRs [95% CI] 1.43 [1.20–
1.71], p < 0.0001; 1.64 [1.37–1.97], p < 0.0001; and 4.74 
[3.86–5.82], < 0.0001) and of only macrovascular disease 
(1.43 [1.30–1.57], p < 0.0001; 2.04 [1.86–2.25], p < 0.0001; 
and 1.26 [1.06–1.51], p = 0.01), compared with patients 
without either of these conditions (Fig.  1; Table  2). The 
highest risks were observed in patients with both condi-
tions at baseline (2.01 [1.65–2.45], p < 0.0001; 2.92 [2.40–
3.55], p < 0.0001; and 6.30 [4.93–8.06], p < 0.0001). There 
was no evidence of interaction between microvascular 
and macrovascular disease at baseline on the risks of all-
cause mortality (p =  0.89), MACE (p =  0.25), or major 
clinical microvascular events (p = 0.75).
Comparable results were observed with secondary end-
points, except for the absence of association of baseline 
macrovascular disease with the risk of ESRD or renal 
death (Table 2).
Additive values of microvascular or macrovascular disease 
at baseline in discrimination and classification of outcomes 
during follow‑up
The addition of microvascular disease (change in c-sta-
tistic [95% CI] 0.005 [0.002–0.008], p  =  0.02) or mac-
rovascular disease (0.005 [0.002–0.007], p  <  0.0001) 
considered separately or together (0.011 [0.007–0.014], 
p < 0.0001) improved the discrimination, as well as the 
classification (IDI: 0.013 [0.010–0.016], p  <  0.001; NRI: 
0.021 [0.011–0.032], p  <  0.001) of the risk of all-cause 
mortality. The addition of ACR (0.010 [0.006–0.014], 
p  <  0.0001) displayed a higher improvement of death 
discrimination than diabetic retinopathy (0.002 [0.001–
0.004], p = 0.01).
The addition of baseline microvascular disease to 
established cardiovascular risk factors improved the dis-
crimination (0.009 [0.003–0.014], p = 0.002) and classi-
fication (IDI: 0.008 [0.006–0.010], p < 0.001; NRI: 0.011 
[0.001–0.020], p  =  0.02) of MACE. The improvement 
in discrimination of MACE was similar after addition 
Page 4 of 9Mohammedi et al. Cardiovasc Diabetol  (2017) 16:95 
of either urinary ACR (0.008 [0.003–0.013], p  =  0.002) 
or diabetic retinopathy (0.007 [0.002–0.011], p = 0.005). 
Adding both urinary ACR and diabetic retinopathy 
together yielded the highest increase in discrimination of 
MACE (0.014 [0.007–0.021], p < 0.0001).
Baseline macrovascular disease modestly enhanced IDI 
(0.002 [0.001–0.002]), p < 0.001 and NRI (0.041 [0.002–
0.087], p < 0.0001), but not discrimination (c-statistic), of 
major clinical microvascular events (Table 3).
Sensitivity analyses
Comparable associations were observed between base-
line microvascular disease, including CKD or peripheral 
diabetic neuropathy, and the risk of outcomes, except for 
myocardial infarction or stroke (Additional file 1: Tables 
S2, S3). Baseline microvascular or macrovascular dis-
ease remained significantly associated with MACE and 
major clinical microvascular events when we corrected 
for competing risk of non-renal and non-cardiovascular 
death (Additional file 1: Table S4).
Discussion
This study demonstrates the independent association of 
microvascular or macrovascular disease at baseline with 
excess risks of all-cause mortality, MACE, and major 
clinical microvascular events in patients with type 2 dia-
betes followed for a median duration of 9.9  years. The 
presence of both conditions led to the highest risks. 
Baseline microvascular disease enhanced discrimination 
and classification of MACE, while baseline macrovas-
cular disease modestly improved classification, but not 
discrimination, of major clinical microvascular events. 
Overall, the improvement in discrimination and clas-
sification of outcomes was quiet modest, but statisti-
cally significant. Interestingly, urinary ACR and diabetic 
retinopathy yielded together the highest improvement of 
Table 1 Clinical characteristics according to microvascular or macrovascular disease at baseline
Comparison of qualitative and quantitative parameters were performed using Chi square and ANOVA tests, respectively. Kruskal–Wallis test was used for variables 
with skewed distribution (urinary albumin-creatinine ratio and triglycerides). p < 0.05 was significant
Established market economies: Australia, Canada, France, Germany, Ireland, Italy, Netherlands, New Zealand, United Kingdom; Eastern Europe: the Czech Republic, 
Estonia, Hungary, Lithuania, Poland, Russia, Slovakia; Asia: Philippines, China, Malaysia, India. eGFR, computed by the Chronic Kidney Disease Epidemiology 
Collaboration equation. ACR, Albumin to Creatinine Ratio. Use of lipid lowering drugs: statins or other hypolipidemic agents
Overall 
(n = 11,140)
History of microvascular or macrovascular disease at baseline
Dual absence 
(n = 6789)
Microvascular 
alone (n = 761)
Macrovascular 
alone (n = 3196)
Both  
(n = 394)
p
Male sex, n (%) 6407 (57.5) 3628 (53.4) 404 (53.1) 2107 (65.9) 268 (68.0) <0.0001
Region of origin: Asia, n (%) 4136 (37.1) 2525 (37.2) 350 (46.0) 1115 (34.9) 146 (37.1) <0.0001
Region of origin: established market 
economies, n (%)
4862 (43.7) 3012 (44.4) 292 (38.4) 1389 (43.5) 169 (42.9)
Region of origin: Eastern Europe, n (%) 2142 (19.2) 1252 (18.4) 119 (15.6) 692 (21.6) 79 (20.0)
Age (years): mean (SD) 65.8 (6.4) 65.9 (6.3) 65.3 (6.4) 65.6 (6.6) 67.0 (6.6) <0.0001
Duration of diabetes (years): mean (SD) 7.9 (6.4) 7.6 (6.1) 10.3 (7.3) 7.7 (6.3) 10.2 (7.2) <0.0001
Body mass index (kg/m2): mean (SD) 28.3 (5.2) 28.4 (5.3) 27.7 (5.2) 28.4 (4.9) 28.2 (5.4) 0.002
Systolic blood pressure (mmHg): mean 
(SD)
145 (22) 145 (21) 149 (24) 144 (22) 148 (23) <0.0001
Diastolic blood pressure (mmHg): mean 
(SD)
81 (11) 81 (11) 81 (12) 80 (11) 81 (11) 0.41
Use of antihypertensive treatment, n (%) 7655 (68.7) 4357 (64.2) 521 (68.5) 2466 (77.2) 311 (78.9) <0.0001
HbA1c (%): mean (SD) 7.5 (1.6) 7.5 (1.6) 7.9 (1.7) 7.4 (1.5) 7.9 (1.6) <0.0001
HbA1c (mmol/mol): mean (SD) 59 (17) 58 (17) 63 (19) 57 (16) 62 (18)
eGFR (ml/min/1.73 m2) 74 (18) 76 (17) 73 (20) 73 (18) 69 (20) <0.0001
Urinary ACR (mg/g): median (Q1, Q3) 15 (7, 40) 13 (7, 31) 49 (12, 390) 15 (7, 36) 86 (13, 461) <0.0001
Serum total cholesterol (mmol/l): mean 
(SD)
5.2 (1.2) 5.3 (1.2) 5.3 (1.2) 5.0 (1.2) 4.9 (1.2) <0.0001
Serum HDL cholesterol (mmol/l): mean 
(SD)
1.3 (0.4) 1.3 (0.4) 1.3 (0.4) 1.2 (0.3) 1.2 (0.3) <0.0001
Serum LDL cholesterol (mmol/l): mean 
(SD)
3.1 (1.0) 3.2 (1.0) 3.2 (1.0) 3.0 (1.1) 2.9 (1.0) <0.0001
Serum triglycerides (mmol/l): median 
(Q1, Q3)
1.6 (1.2, 2.3) 1.6 (1.2, 2.3) 1.6 (1.2, 2.3) 1.7 (1.2, 2.3) 1.6 (1.1, 2.2) 0.05
History of ever smoking, n (%) 4674 (42.0) 2702 (39.8) 271 (35.6) 1529 (47.8) 172 (43.7) <0.0001
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MACE supporting their additive value in the prediction 
of macrovascular disease. Of note, both ACR and retin-
opathy were independent components of the 10-year 
prognostic vascular risk score recently reported by our 
group in the ADVANCE-ON stud [14].
Microvascular disease and risk of MACE
Our findings support previous studies showing that 
microvascular disease is an important predictor of future 
macrovascular disease and death [6, 15]. ADVANCE par-
ticipants with microvascular disease alone at baseline 
displayed similar hazard ratios for all-cause mortality or 
MACE, compared to those with macrovascular disease 
alone, suggesting that microvascular impairment plays an 
important role in the development of diabetic angiopathy. 
A recent population-based cohort study has shown that 
retinal and skin microvascular abnormalities occurred 
early in prediabetes, were more severe in type 2 diabetes, 
and may contribute to the development of cardiovascular 
disease [16]. Other studies reported a high prevalence of 
coronary microvascular dysfunction in patients with type 
2 diabetes free for known cardiovascular disease [17, 18].
Macrovascular disease and risk of major clinical 
microvascular events
We evaluated, for the first time, the impact of macro-
vascular disease at baseline on the 9.9-year risk of major 
clinical microvascular events in patients with type 2 dia-
betes. Macrovascular disease at baseline was significantly 
associated with an elevated risk of the composite major 
microvascular endpoint, as well as retinal photocoagu-
lation or blindness, but not ESRD or renal death. We 
recently reported that the history of peripheral arterial 
disease was associated with the risk of severe diabetic 
retinopathy, but not renal endpoints in ADVANCE and 
ADVANCE-ON studies [19]. Based on their poor prog-
nosis, patients with chronic macrovascular disease at 
baseline may have died before experiencing ESRD dur-
ing the follow-up. The impact of macrovasular disease 
on the risk of major clinical microvascular events seems 
to be weaker than the effect of microvascular disease on 
MACE risk, but there was no evidence of an interaction 
between the two conditions at baseline on the risk of any 
measured outcome. Despite their common background, 
these conditions had independent effects, suggesting that 
different mechanisms may be involved in the impact of 
microvascular and macrovascular disease on future vas-
cular events. Hence there is a need to evaluate new pre-
dictors for both microvascular and macrovascular events. 
For instance, a high index of microcirculatory resistance 
and low coronary flow reserve were recently found asso-
ciated with poor cardiovascular prognosis in patients 
with intermediate coronary stenosis (29% with type 2 
diabetes) [20].
Physiopathological mechanisms linking microvascular 
and macrovascular disease
Several pathways may explain the relationship 
between microvascular and macrovascular disease in 
patients with diabetes. Diabetic microvascular com-
plications are mainly caused by prolonged exposure 
to high glucose levels. Diabetes is also associated with 
Fig. 1 Cumulative incidence of outcomes during follow-up accord-
ing to status of microvascular and macrovascular disease at baseline. 
a All-cause mortality. b Major macrovascular events. c Major clinical 
microvascular disease (p < 0.0001 for all). Black line absence of both 
macrovascular and microvascular disease. Blue line presence of micro-
vascular disease alone. Green line presence of macrovascular disease 
alone. Red line presence of both microvascular and macrovascular 
disease
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accelerated atherosclerosis affecting large vessels [21, 
22]. Atherosclerosis is more prevalent in diabetic patients 
with microvascular disease compared to those without 
[21, 22]. However, it is still unknown why intensive glu-
cose control does not yield the same benefit on macro-
vascular events as observed for microvascular outcomes 
[23]. Chronic hyperglycaemia causes vascular damage 
through activation of major biochemical paths includ-
ing polyol pathway flux, increased formation of advanced 
glycation end products (AGEs), increased expression of 
AGEs receptor and its activating ligands, activation of 
protein kinase C isoforms, and overactivity of the hexosa-
mine pathway [24]. Numerous lines of evidence suggest 
that these biochemical abnormalities may be activated 
by mitochondrial overproduction of reactive oxygen spe-
cies (ROS) induced by hyperglycaemia [25]. The excess 
of ROS production with decreased in antioxidant capac-
ity lead to oxidative stress, which plays an important 
role in the premature vascular morbidity and mortality 
in patients with diabetes [26]. Oxidative stress impairs 
endothelial function and endothelium-dependent vaso-
dilation by inactivation of NO, and induces cell prolif-
eration, hypertrophy, cardiac remodeling, apoptosis, 
and low-grade inflammation in endothelial and smooth 
cells of the vascular wall [27–30]. Moreover, oxidative 
stress is associated with many other accelerating condi-
tions including insulin resistance, metabolic syndrome, 
hypertension, dyslipidaemia, and obesity, leading to 
both microvascular and macrovascular disease [25, 31]. 
The depletion of circulating stem cells may also explain 
the association between microvascular and macrovascu-
lar disease. A recent study has shown lower  CD34+ and 
 CD34+CD133+ cells in type 2 diabetic patients with car-
diovascular events compared to those without [32]. The 
reduced levels of circulating progenitor cells improve 
the prediction of both macrovascular and microvascular 
events [32, 33]. The remodeling of bone marrow involves 
neurovascular changes and vascular abnormalities com-
parable to the known microangiopathy seen in the kidney 
and the retina [34].
Strengths and limitations
The main strength of our study is the evaluation of the 
individual and the combined impact of microvascular 
and macrovascular disease at baseline on the risk of death 
and major microvascular and macrovascular outcomes in 
a large international cohort of patients with type 2 diabe-
tes followed for a median duration of 9.9 years. The main 
Table 3 Harrell’s c-statistics, NRI, IDI for risk of major outcomes according to traditional risk factors without and with his-
tory of microvascular or macrovascular disease at baseline
Basic model: sex, age, region of origin, BMI, duration of diabetes, HbA1c, systolic blood pressure, antihypertensive treatment, eGFR and its square, urinary albumin-
creatinine ratio (for major clinical microvascular events), LDL- and HDL-cholesterol, history of ever smoking, and study allocations. IDI (integrated discrimination 
improvement) and NRI (net reclassification improvement) tests performed for basic model plus history of microvascular (risk of MACE), macrovascular disease (risk of 
major clinical microvascular events) or both (risk of all-cause mortality) at baseline, compared to basic model alone. Analyses performed in patients free of baseline 
history of microvascular disease (risk of major clinical microvascular events), or free of macrovascular disease (risk of MACE)
Risk of all‑cause mortality P
C-statistic (95% CI) for basic model 0.704 (0.693 to 0.716)
Change in C-statistic (95% CI) for basic model + microvascular disease 0.005 (0.002 to 0.008) 0.02
Change in C-statistic (95% CI) for basic model + macrovascular disease 0.005 (0.002 to 0.007) <0.0001
Change in C-statistic (95% CI) for basic model + microvascular disease + macrovascular disease 0.011 (0.007 to 0.014) <0.0001
IDI (95% CI) 0.013 (0.010 to 0.016) <0.001
Continuous NRI (95% CI) 0.275 (0.227 to 0.325) <0.001
Categorical NRI (95% CI) 0.021 (0.011 to 0.032) <0.001
Risk of major macrovascular events (MACE)
C-statistic (95% CI) for basic model 0.648 (0.631 to 0.665)
Change in C-statistic (95% CI) for basic model + microvascular disease 0.009 (0.003 to 0.014) 0.002
IDI (95% CI) 0.008 (0.006 to 0.010) <0.001
Continuous NRI (95% CI) 0.120 (0.073 to 0.167) <0.001
Categorical NRI (95% CI) 0.011 (0.001 to 0.020) 0.02
Risk of major clinical microvascular events
C-statistic (95% CI) for basic model 0.664 (0.639 to 0.689)
Change in C-statistic (95% CI) for basic model + macrovascular disease 0.004 (−0.003 to 0.011) 0.25
IDI (95% CI) 0.002 (0.001 to 0.002) <0.001
Continuous NRI (95% CI) 0.211 (0.112 to 0.305) <0.001
Categorical NRI (95% CI) 0.041 (0.002 to 0.087) 0.03
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limitation is the absence of biochemical renal assessment 
during the ADVANCE-ON follow-up, which may under-
estimate the association between baseline macrovascu-
lar disease and kidney disease. Furthermore, peripheral 
diabetic neuropathy was not investigated as an outcome 
in the post-trial, ADVANCE-ON, observational study. 
Although comparable findings were observed when we 
evaluated the associations of microvascular disease at 
baseline, including the history of peripheral diabetic neu-
ropathy, with the main outcomes.
Conclusion
The presence of microvascular or macrovascular disease 
at baseline is independently associated with increased 
risk of death, MACE, and major clinical microvascu-
lar events in people with type 2 diabetes followed for a 
median duration of 9.9 years, and their coexistence has an 
additive prognostic value. These findings encourage con-
sideration of prior microvascular disease including reti-
nal status, in addition to traditional cardiovascular risk 
factors, in selecting participants for forthcoming clinical 
trials aiming to assess vascular endpoints in patients with 
type 2 diabetes.
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